| Name | Title | Contact Details |
|---|
CompuGroup Medical is a global eHealth provider with a comprehensive portfolio of cutting-edge IT solutions for the healthcare industry. Our Meaningful Use and ICD-10 enabled products allow users to securely store, exchange and access important clinical and financial insight anytime and anywhere. We connect doctors, hospitals, community health facilities, dentists, pharmacists, health insurers and other service providers to create an integrated network of all healthcare stakeholders. As a result, we can help these organizations improve efficiency, optimize care and increase patient satisfaction while also improving profitability. Our market-leading solutions include everything from electronic health records to innovative practice management systems. These solutions are present in over 400,000 practices and healthcare organizations worldwide. We are also proud to maintain and sustain long-term relationships with our clients, many of whom have been using our products for decades. Our dedicated, knowledgeable team consistently delivers innovative products and services with the customer in mind, knowing that in addition to running an effective business, their main focus is to heal the patient. We share that same passion and it drives everything we do. As an owner-led and publicly traded company, CGM uniquely combines the personal touch of a local business with the strength of a global entity. We are committed to meeting and exceeding our clients` expectations, and our goal is to become the #1 choice for all healthcare providers in the United States – a position we have already achieved in many other countries around the world.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
Columbine Care Ctr East is a Fort Collins, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TFS was founded in 1996 and has grown to become a leading global mid-size clinical CRO focusing on small and mid-size life science customers. TFS employs more than 700 professionals throughout 21 countries and currently delivers clinical research services in more than 40 countries.